AI Science Tracker
EN

Shizuoka Cancer Center

1 discovery from 2023

Discoveries

Machine-learned immune-cell quantification stratifies lung-cancer prognosis

Source check: Source checked. Not independent scientific confirmation.

Finding: HALO random-forest image analysis quantified immune-cell densities and PD-L1 staining in resected non-small-cell lung cancers from 165 patients. Combined epithelial/stromal CD8-positive lymphocyte density and epithelial PD-L1 proportion were independently associated with disease-free survival. This single-centre retrospective study used manual tissue annotations and did not establish benefit from selecting postoperative treatment by these measurements.

Technology: HALO; random forest

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
HALO ensembles random forests to distinguish tissue compartments and quantify CD8/Foxp3/PD-L1 signals for prognostic association.
Test and result
Retrospective 165-patient immune-marker measurements and adjusted survival association.
Limitation / still unknown
Single-centre selection, annotation bias and clinical decision benefit remain unestablished.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13659040/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 21 Nov 2026. Review scope: Primary full paper relevant model Methods, study Results and limitations; exact primary front-matter identity and Europe PMC metadata checked..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.